title: Oral combination therapy in primary care.
abstract: Diabetes is a multifactorial disease, with multiple pathophysiologic abnormalities. This means that a combination of drugs, acting upon as many pathologic mechanisms as possible, is necessary for optimal management of the syndrome. This article discusses how a rational combination of oral anti-diabetic drugs can be chosen and used in primary care practice.
authors.affiliation: Department of Endocrinology, Bharti Hospital & BRIDE, Karnal.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
authors.affiliation: Department of Medicine, Government Medical College, Chandigarh, India.
authors.forename: Yashdeep
authors.initials: Y
authors.lastname: Gupta
mesh_terms: D000068896:Canagliflozin / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D065089:Glycoside Hydrolase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D000077205:Pioglitazone; D011320:Primary Health Care; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D045162:Thiazolidinediones / Q000627:therapeutic use
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D004338:Drug Combinations; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D000068896:Canagliflozin; D008687:Metformin; D000077205:Pioglitazone
keywords: Metformin, Sulfonylureas, Pioglitazone, Alpha glucosidase inhibitors, DPP4 inhibitors, Oral anti-diabetic drugs.